Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Tuberculosis

  Free Subscription


06.03.2017

2 Antimicrob Agents Chemother
18 Int J Tuberc Lung Dis
1 J Clin Microbiol
1 J Infect
3 Lancet Infect Dis
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Antimicrob Agents Chemother

  1. RAMACHANDRAN G, Kumar AK, Chandrasekaran V, Kannan T, et al
    Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India.
    Antimicrob Agents Chemother. 2017 Feb 27. pii: AAC.02464.
    PubMed     Text format     Abstract available

  2. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
    Erratum for Velasquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    


    Int J Tuberc Lung Dis

  3. BRYLA M, Dziankowska-Zaborszczyk E, Maniecka-Bryla I
    Standard expected years of life lost due to tuberculosis in Poland.
    Int J Tuberc Lung Dis. 2017;21:202-207.
    PubMed     Text format     Abstract available

  4. STAGG HR, Lipman MC, McHugh TD, Jenkins HE, et al
    Isoniazid-resistant tuberculosis: a cause for concern?
    Int J Tuberc Lung Dis. 2017;21:129-139.
    PubMed     Text format     Abstract available

  5. CLAASSENS MM, Dunbar R, Yang B, Lombard CJ, et al
    Scanty smears associated with initial loss to follow-up in South African tuberculosis patients.
    Int J Tuberc Lung Dis. 2017;21:196-201.
    PubMed     Text format     Abstract available

  6. IZUMI K, Ohkado A, Uchimura K, Kawatsu L, et al
    Evaluation of tuberculosis contact investigations in Japan.
    Int J Tuberc Lung Dis. 2017;21:188-195.
    PubMed     Text format     Abstract available

  7. HTET KK, Liabsuetrakul T, Thein S
    Cost-effectiveness of a new strategy to detect pulmonary tuberculosis in household contacts in Myanmar.
    Int J Tuberc Lung Dis. 2017;21:181-187.
    PubMed     Text format     Abstract available

  8. GUGLIELMETTI L, Hewison C, Avaliani Z, Hughes J, et al
    Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
    Int J Tuberc Lung Dis. 2017;21:167-174.
    PubMed     Text format     Abstract available

  9. CHIPINDURO M, Mateveke K, Makamure B, Ferrand RA, et al
    Stool Xpert(R) MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis at primary clinics in Zimbabwe.
    Int J Tuberc Lung Dis. 2017;21:161-166.
    PubMed     Text format     Abstract available

  10. CHIANG SS, Roche S, Contreras C, Del Castillo H, et al
    Barriers to the treatment of childhood tuberculous infection and tuberculosis disease: a qualitative study.
    Int J Tuberc Lung Dis. 2017;21:154-160.
    PubMed     Text format     Abstract available

  11. LOPEZ C, Bertram-Farough A, Heywood D, Dawson L, et al
    Knowing about you: eliciting dimensions of personhood within tuberculosis care.
    Int J Tuberc Lung Dis. 2017;21:149-153.
    PubMed     Text format     Abstract available

  12. MCEBULA V, Crowther NJ, Nagel SE, George JA, et al
    Diabetes and abnormal glucose tolerance in subjects with tuberculosis in a South African urban center.
    Int J Tuberc Lung Dis. 2017;21:208-213.
    PubMed     Text format     Abstract available

  13. PRIYADARSHINI P, Tiwari K, Das A, Kumar D, et al
    Evaluation of highly conserved hsp65-specific nested PCR primers for diagnosing Mycobacterium tuberculosis.
    Int J Tuberc Lung Dis. 2017;21:214-217.
    PubMed     Text format     Abstract available

  14. O'DONNELL MR, Padayatchi N, Metcalfe JZ
    Elucidating the role of clofazimine for the treatment of tuberculosis.
    Int J Tuberc Lung Dis. 2016;20:52-57.
    PubMed     Text format     Abstract available

  15. NUERMBERGER E
    Evolving strategies for dose optimization of linezolid for treatment of tuberculosis.
    Int J Tuberc Lung Dis. 2016;20:48-51.
    PubMed     Text format     Abstract available

  16. STERLING TR
    Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2016;20:42-47.
    PubMed     Text format     Abstract available

  17. MURRAY S, Mendel C, Spigelman M
    TB Alliance regimen development for multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2016;20:38-41.
    PubMed     Text format     Abstract available

  18. GUPTA R, Wells CD, Hittel N, Hafkin J, et al
    Delamanid in the treatment of multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2016;20:33-37.
    PubMed     Text format     Abstract available

  19. MILSTEIN M, Brzezinski A, Varaine F, Mitnick CD, et al
    (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2016;20:18-23.
    PubMed     Text format     Abstract available

  20. PARENT SN, Ehrlich R, Baxter V, Kannemeyer N, et al
    Participatory theatre and tuberculosis: a feasibility study with South African health care workers.
    Int J Tuberc Lung Dis. 2017;21:140-148.
    PubMed     Text format     Abstract available


    J Clin Microbiol

  21. ROCKWOOD N, Wojno J, Ghebrekristos Y, Nicol MP, et al
    Utility of second generation line probe assay (Hain MTBDRplus) directly on 2-month sputa specimens to monitor tuberculosis treatment response.
    J Clin Microbiol. 2017 Mar 1. pii: JCM.00025-17. doi: 10.1128/JCM.00025.
    PubMed     Text format     Abstract available


    J Infect

  22. PARCELL BJ, Jarchow-MacDonald A, Seagar AL, Laurenson I, et al
    Three Year Evaluation of Xpert MTB/RIF in a Low Prevalence Tuberculosis Setting: a Scottish Perspective.
    J Infect. 2017 Feb 22. pii: S0163-4453(17)30054.
    PubMed     Text format     Abstract available


    Lancet Infect Dis

  23. MENZIES D
    Isoniazid-resistant tuberculosis treatment with first-line drugs-Author reply.
    Lancet Infect Dis. 2017;17:260.
    PubMed     Text format    

  24. ANDRE E, Martin A
    Isoniazid-resistant tuberculosis treatment with first-line drugs.
    Lancet Infect Dis. 2017;17:258-259.
    PubMed     Text format    

  25. CHIEN JY, Wang JY
    Isoniazid-resistant tuberculosis treatment with first-line drugs.
    Lancet Infect Dis. 2017;17:259-260.
    PubMed     Text format    


    PLoS One

  26. NABETA P, Havumaki J, Ha DT, Caceres T, et al
    Feasibility of the TBDx automated digital microscopy system for the diagnosis of pulmonary tuberculosis.
    PLoS One. 2017;12:e0173092.
    PubMed     Text format     Abstract available

  27. HERMOSILLA S, You P, Aifah A, Abildayev T, et al
    Identifying risk factors associated with smear positivity of pulmonary tuberculosis in Kazakhstan.
    PLoS One. 2017;12:e0172942.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: